Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

被引：5

作者：

Lodise, Thomas ^{[1
]}

Colman, Sam ^{[2
]}

Stein, Daniel S. ^{[3
]}

Fitts, David ^{[3
]}

Goldberg, Lisa ^{[3
]}

Alexander, Elizabeth ^{[3
]}

Scoble, Patrick J. ^{[3
]}

Schranz, Jennifer ^{[3
]}

机构：

[1] Albany Coll Pharm & Hlth Sci, 108 New Scotland Ave, Albany, NY 12208 USA

[2] Covance Market Access Serv Inc, Gaithersburg, MD USA

[3] Nabriva Therapeut US Inc, King Of Prussia, PA USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2020年 / 7卷 / 05期

关键词：

community-acquired bacterial pneumonia; fluoroquinolones; lefamulin; patient discharge; time to clinical response; DISCHARGE; RISK; CEFTRIAXONE; MANAGEMENT; STABILITY; OUTCOMES; RULE;

D O I：

10.1093/ofid/ofaa145

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Time to clinical response, a proxy for hospital "discharge readiness," was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical response (4 days) was observed in both treatment groups.

引用

页数：4

共 4 条

[1] Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
Lodise, Thomas P.
Colman, Sam
Alexander, Elizabeth
Stein, Daniel S.
Fitts, David
Goldberg, Lisa
Schranz, Jennifer
OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (06):
[2] Assessment of Time to Clinical Response, a Proxy for Discharge Readiness, among Hospitalized Patients with Community-Acquired Pneumonia Who Received either Ceftaroline Fosamil or Ceftriaxone in Two Phase III FOCUS Trials
Lodise, Thomas P.
Anzueto, Antonio R.
Weber, David J.
Shorr, Andrew F.
Yang, Min
Smith, Alexander
Zhao, Qi
Huang, Xingyue
File, Thomas M.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (02) : 1119 - 1126
[3] Relationship between Time to Clinical Response and Outcomes among Pneumonia Outcomes Research Team (PORT) Risk Class III and IV Hospitalized Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and Azithromycin
Zasowski, Evan
Butterfield, Jill M.
McNutt, Louise-Ann
Cohen, Jason
Cosler, Leon
Pai, Manjunath P.
Gottwald, Joseph
Chen, Wen Zhen
Lodise, Thomas P.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (07) : 3804 - 3813
[4] Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia
Rank, Douglas R.
Friedland, H. David
Laudano, Joseph B.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 : III53 - III59

← 1 →